<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn fn-type="other">
  <p>
   <bold>Handling editor:</bold> Seye Abimbola
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Contributors:</bold> DASL: data analysis, interpretation, study design, drafting and revision of the manuscript; PV: data analysis, interpretation, study design and revision of the manuscript; AM and DCA: interpretation, drafting and revision of the manuscript; CRM: conception of the study, interpretation, study design and revision of the manuscript.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Funding:</bold> This work was supported by a grant from the National Health and Medical Research Council (NHRMC) Centre for Research Excellence in Integrated Systems for Epidemic Response (grant number 1107393). CRM is supported by a NHMRC Principal Research Fellowship, grant number 1137582.
  </p>
 </fn>
 <fn fn-type="COI-statement">
  <p>
   <bold>Competing interests:</bold> CRM has received funding for investigator-driven research from Sequris and Sanofi unrelated to this study. CRM has also been on advisory boards for the same companies.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Patient consent for publication:</bold> Not required.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Data availability statement:</bold> All data collected for the purpose of this study are publicly available. The EpiRisk Tool itself will be made available via an online system in the future.
  </p>
 </fn>
</fn-group>
